Introduction
Fibrostenosing Crohn’s Disease (FSCD) will affect over 50% of patients during their disease course1. While cross sectional imaging accurately identifies luminal narrowing, distinguishing predominant inflammation from underlying fibrosis remains the critical diagnostic challenge2. Gallium-68-labeled fibroblast activation protein inhibitor ([68Ga]FAPI) is a novel positron-emitting radiotracer that binds to fibroblast activation protein (FAP) on activated fibroblasts. By specifically binding to these key drivers of extracellular matrix deposition, [68Ga]FAPI PET-MRI offers a unique opportunity to visualise and quantify active fibrosis within the bowel wall3,4.
Aims & Methods
Aim: To evaluate the ability of [68Ga]FAPI PET-MRI to differentiate FSCD from inflammatory CD (ICD) phenotypes and non-IBD controls.
Methods: Participants were recruited from the FATE-CD study, a prospective observational cohort study (2024–2026). All patients underwent [68Ga]FAPI PET-MRI. All CD patients had a Montreal L1 phenotype (ileal disease) and were categorized into three groups: FSCD (n=7 Montreal B2 and n=2 B2&B3) and inflammatory CD (n=6, Montreal B1) and non-IBD controls (n=9), all of whom were female, were recruited from the PET-ENDO study. PET image analysis and quantification (peak standardized uptake value; SUVpeak) was performed using Pmod software (v4.2). In silico analyses were performed from publicly available single-cell and spatial transcriptomics datasets of CD strictures (Kong et al5).
Results
Twenty-four participants had a median age 44 [interquartile interval 36-50] years. No differences were observed between FSCD and ICD for age (P=0.479), body-mass index (P=0.607), smoking status (P=1) and current medication use (P=0.397). FSCD were exposed to multiple therapies during their disease course (median 3 [2-3]).
[68Ga]FAPI was elevated in FSCD cases compared to inflammatory CD (median SUVpeak 3.0 vs 1.1, Wilcoxon P=0.012) and FSCD cases compared to non-CD control subjects (median SUVpeak 3.0 vs 1.3, Wilcoxon P = 0.008).
To provide molecular validation, we interrogated a publicly available single-cell transcriptomic dataset of Crohn’s strictures (Kong et al., Nature Genetics 2025), comprising 61 intestinal samples from FSCD and non-fibrotic CD. This demonstrated that FAP expression was enriched within fibroblast subpopulations that spatially localized to fibrotic niches (5.2-fold increase vs non-fibrotic tissue, P<0.001), supporting the biological specificity of FAPI uptake within FSCD observed on PET-MRI.
Conclusion
[68Ga]FAPI PET-MRI appears to discriminate between fibrotic and inflammatory Crohn’s disease, providing a non-invasive readout of pathogenic FAP+ fibroblast activity. These findings suggest that [68Ga]FAPI PET-MRI is a promising biomarker for identifying stricturing phenotypes and warrants validation in larger cohorts.
References
- Bettenworth, D. et al. Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. Gut 68, 1115–1126 (2019).
- Bettenworth, D. et al. A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice. Nat Rev Gastroenterol Hepatol 21, 572–584 (2024).
- Barton, A. K. et al. Myocardial Fibroblast Activation After Acute Myocardial Infarction. Journal of the American College of Cardiology 85, 578–591 (2025).
- Debus, J. et al. 68Ga-FAPI PET/CT for non-invasive characterization and activity assessment of ulcerative colitis and Crohn´s disease. Eur J Nucl Med Mol Imaging 53, 3258–3270 (2026).
- Kong, L. et al. Single-cell and spatial transcriptomics of stricturing Crohn’s disease highlights a fibrosis-associated network. Nat Genet 57, 1742–1753 (2025).
Disclosure
Nil